Associated tags: Neoplasm, Acute myeloid leukemia, Virus, STS, Biotechnology, AML, Pharmaceutical industry, Cancer, Brain, T-cell lymphoma, COVID-19, Antimetabolite, Conference, Patient, Safety
Locations: TEXAS, EUROPE, UNITED STATES, EUROPEAN UNION, US, SLOAN, NEW YORK
Retrieved on:
Thursday, January 20, 2022
Antimetabolite,
Pancreas,
Conference,
LinkedIn,
Liver,
Interest,
COVID-19,
Virus,
T-cell lymphoma,
CEO,
AML,
Cancer,
Acute myeloid leukemia,
Investor,
Q&A,
Doxorubicin,
Company,
STS,
Neoplasm,
Twitter,
Virtual,
Brain,
Pharmaceutical industry,
Facebook As part of the virtual event, the Company will provide a corporate presentation, followed by a moderated interactive Q&A session.
Key Points:
- As part of the virtual event, the Company will provide a corporate presentation, followed by a moderated interactive Q&A session.
- In addition to the moderated portion of the event, all investors and interested parties will have the opportunity to submit questions live during the event.
- Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at virtualinvestorco.com .
- For more information about the Company, please visit www.moleculin.com and connect on Twitter , LinkedIn and Facebook .
Retrieved on:
Tuesday, January 18, 2022
Securities Exchange Act of 1934,
Antimetabolite,
Anthracycline,
LinkedIn,
Private Securities Litigation Reform Act,
SEC,
Patient,
AML,
U.S. Securities and Exchange Commission,
US Foods,
Cancer,
European,
Face,
AST,
Clinical trial,
Incidence,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Form 10-K,
COVID-19,
Cardiotoxicity,
T-cell lymphoma,
Hair loss,
Safety,
Risk,
DLT,
ALT,
MTD,
Lung,
Cleveland Clinic,
Company,
Alvin J. Siteman Cancer Center,
STS,
Food,
FDA,
Principal,
Brain,
Cleveland,
Forward-looking statement,
Review,
Doxorubicin,
Toxicity,
Drug Quality and Security Act,
Index (publishing),
Securities Act of 1933,
Virus,
CEO,
Acute myeloid leukemia,
Quality of life,
Neoplasm,
Twitter,
Security (finance),
Hair,
Patient safety,
Terminology,
Pharmaceutical industry,
Facebook,
Annamycin Two of the three clinical trials, as described more fully below, are ongoing and the data from those trials remain preliminary and are subject to change and future updates.
Key Points:
- Two of the three clinical trials, as described more fully below, are ongoing and the data from those trials remain preliminary and are subject to change and future updates.
- The ongoing trials are both in the dose escalation phase (Phase 1) with the goal of determining the recommended Phase 2 dose (RP2D).
- For more information about the Phase 1b/2 study evaluating Annamycin for the treatment of STS lung metastases, please visit clinicaltrials.gov and reference identifier NCT04887298.
- Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
Retrieved on:
Monday, December 27, 2021
LinkedIn,
Index (publishing),
Toxicity,
COVID-19,
Vital signs,
Antimetabolite,
Cardiotoxicity,
Securities Exchange Act of 1934,
T-cell lymphoma,
RECIST,
Population,
Virus,
PFS,
Patient,
Food,
Doxorubicin,
SEC,
Terminology,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
ECOG,
STS,
Progression-free survival,
Anthracycline,
CEO,
Liu v. Securities and Exchange Commission,
Security (finance),
HIV disease progression rates,
Clinical trial,
Treatment,
PR,
Cancer,
Safety,
Risk,
Eastern Cooperative Oncology Group,
CT,
Drug Quality and Security Act,
Brain,
MTD,
Securities Act of 1933,
Forward-looking statement,
Form 10-K,
Neoplasm,
Lung,
AML,
Wireless ambulatory ECG,
Private Securities Litigation Reform Act,
AES,
Acute myeloid leukemia,
Physical examination,
ECHO,
Twitter,
Company,
Pharmaceutical industry,
Audit,
Medical imaging,
Facebook Phase 1b/2 clinical trial as it concluded the safety review of the third cohort and opens the fourth cohort in a dose escalation trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases, which continues to document preliminary clinical activity for this drug.
Key Points:
- Phase 1b/2 clinical trial as it concluded the safety review of the third cohort and opens the fourth cohort in a dose escalation trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases, which continues to document preliminary clinical activity for this drug.
- "Even though this is still early in the Phase 1b portion of the trial, the data continue to be encouraging.
- For more information about the Phase 1b/2 study evaluating Annamycin for the treatment of STS lung metastases, please visit clinicaltrials.gov and reference identifier NCT04887298.
- Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
Retrieved on:
Wednesday, December 1, 2021
Patient,
Private Securities Litigation Reform Act,
Security (finance),
Pancreatic cancer,
CEO,
Safety,
Cancer,
Drug Quality and Security Act,
Risk,
US Foods,
Investigational New Drug,
Forward-looking statement,
GBM,
Company,
Neoplasm,
T-cell lymphoma,
AML,
Glioblastoma,
Virus,
IND,
Acute myeloid leukemia,
SEC,
Pharmacokinetics,
Antimetabolite,
Securities Act of 1933,
U.S. Securities and Exchange Commission,
COVID-19,
Securities Exchange Act of 1934,
Survival,
Twitter,
STS,
Adult,
Incidence,
United Kingdom,
Terminology,
United,
FDA,
Form 10-K,
Person,
LinkedIn,
Glioma,
Brain,
Food,
Pharmaceutical industry HOUSTON, Dec. 1, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) is allowing the Company's Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward. With this IND now cleared, Moleculin plans to initiate a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1122 in adult patients with GBM.
Key Points:
- The Company believes WP1122 has significant potential as both an antiviral therapy and as a cancer therapy.
- Moleculin recently announced its plans to initiate a Phase 1a clinical trial of WP1122 in healthy volunteers in the United Kingdom to facilitate future testing in COVID-19 patients.
- This new US IND sets the stage for parallel development of WP1122 as a cancer therapy.
- "This IND underscores our dual pronged approach to the development of WP1122 for the treatment of both certain types of cancers and viruses.
Retrieved on:
Friday, November 12, 2021
AML,
Virtual,
Investor,
MD,
Round Table,
CEO,
Liver,
Acute myeloid leukemia,
T-cell lymphoma,
Senior,
Brain,
COVID-19,
Cancer,
Twitter,
Neoplasm,
Company,
LinkedIn,
Virus,
Q&A,
Antimetabolite,
Doxorubicin,
STS,
Pancreas,
Interest,
Pharmaceutical industry As part of the virtual event, the Company will provide a brief presentation, followed by a moderated Roundtable discussion and an interactive Q&A session.
Key Points:
- As part of the virtual event, the Company will provide a brief presentation, followed by a moderated Roundtable discussion and an interactive Q&A session.
- In addition to the moderated portion of the event, all investors and interested parties will have the opportunity to submit questions live during the event.
- Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at virtualinvestorco.com .
- A live video webcast of the Roundtable Event will be available on the Events page of the Investors section of the Company's website ( moleculin.com ).
Retrieved on:
Tuesday, October 19, 2021
IND,
Virus,
Twitter,
AML,
STS,
Antimetabolite,
Security (finance),
Drug discovery,
Terminology,
Female,
Human,
Patient,
MAD,
Seriousness,
Medication,
Safety,
AES,
Pharmacokinetics,
Cancer,
Private Securities Litigation Reform Act,
COVID-19,
LinkedIn,
ACT Biotech Inc,
Drug Quality and Security Act,
MHRA,
Risk,
Vital signs,
SEC,
Physical examination,
Medicines and Healthcare products Regulatory Agency,
Liver,
Doxorubicin,
Volunteering,
Glycolysis,
Neoplasm,
U.S. Securities and Exchange Commission,
SAD,
Securities Exchange Act of 1934,
CEO,
T-cell lymphoma,
Forward-looking statement,
Pancreas,
Mouse,
Brain,
Severe acute respiratory syndrome coronavirus 2,
Program,
Form 10-K,
Acute myeloid leukemia,
PK,
Securities Act of 1933,
Culture,
Glycosylation,
Company,
Pharmaceutical industry,
Vaccine "We are incredibly grateful for the ongoing efforts and discussions the MHRA has engaged in with us to advance this important program.
Key Points:
- "We are incredibly grateful for the ongoing efforts and discussions the MHRA has engaged in with us to advance this important program.
- Coronaviruses, including SARS-CoV-2, are highly dependent upon glycosylation to form structurally and functionally different essential glycoproteins, as well as glycolysis for energy production.
- The Phase 1a study in healthy human volunteers will investigate the effects of a single ascending dose (SAD) and multiple days of ascending dosing (MAD) of WP1122 administered as an oral solution.
- Moleculin Biotech is also in the process of identifying additional countries where potential future Phase 2 COVID-19 clinical studies could occur.
AES,
Lung,
Vital signs,
HIV disease progression rates,
Securities Exchange Act of 1934,
Terminology,
Brain,
Cancer,
Private Securities Litigation Reform Act,
LinkedIn,
AML,
RECIST,
Risk,
Antimetabolite,
Cardiotoxicity,
Security (finance),
Eastern Cooperative Oncology Group,
ECOG,
Securities Act of 1933,
Optimism,
SEC,
Anthracycline,
Treatment,
T-cell lymphoma,
Drug Quality and Security Act,
PR,
Wireless ambulatory ECG,
MTD,
PFS,
Patient,
Physical examination,
Progression-free survival,
Clinical trial,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Index (publishing),
Food,
Liu v. Securities and Exchange Commission,
Toxicity,
STS,
Form 10-K,
Company,
Forward-looking statement,
Acute myeloid leukemia,
CEO,
Twitter,
Safety,
ECHO,
Neoplasm,
Doxorubicin,
Virus,
COVID-19,
Pharmaceutical industry,
Audit,
Medical imaging HOUSTON, Oct. 18, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported interim results from its U.S. Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases, which documented preliminary clinical activity for Annamycin.
Key Points:
- Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases, which documented preliminary clinical activity for Annamycin.
- "To witness the activity of Annamycin in the treatment of STS lung metastases, even this early in a Phase 1 trial, we believe is encouraging.
- These interim data bolster our optimism about the potential for Annamycin to address the limitations with the current standard-of-care treatment options for STS lung metastases.
- Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
Retrieved on:
Monday, September 27, 2021
ACT Biotech Inc,
Cancer,
Neoplasm,
Brain,
AML,
Investor,
Conference,
STS,
LinkedIn,
Virus,
Twitter,
Company,
Liver,
COVID-19,
Acute myeloid leukemia,
Pancreas,
Doxorubicin,
T-cell lymphoma,
Antimetabolite,
Pharmaceutical industry,
Vaccine HOUSTON, Sept. 27, 2021 /PRNewswire/ --Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021 at 8:40 AM ET.
Key Points:
- HOUSTON, Sept. 27, 2021 /PRNewswire/ --Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021 at 8:40 AM ET.
- In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
- The live webcast of the presentation will be accessible on the Events page in the Investors section of the Company's website ( www.moleculin.com ).
- For more information about the Company, please visit www.moleculin.com and connect on Twitter , LinkedIn and Facebook .
Retrieved on:
Friday, September 17, 2021
Cancer,
Liver,
Medtech,
AML,
Investor,
Company,
Brain,
LinkedIn,
Antimetabolite,
Neoplasm,
Doxorubicin,
Acute myeloid leukemia,
COVID-19,
T-cell lymphoma,
Twitter,
Virus,
STS,
ACT Biotech Inc,
Pancreas,
Pharmaceutical industry,
Vaccine HOUSTON, Sept. 17, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 20, 2021 at 4:35 PM ET.
Key Points:
- HOUSTON, Sept. 17, 2021 /PRNewswire/ --Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 20, 2021 at 4:35 PM ET.
- The live webcast of the presentation will be accessible on the the Events page in the Investors section of the Company's website ( www.moleculin.com ).
- The Company's lead program, Annamycin is a next-generation anthracycline designed to be noncardiotoxic and to avoid multidrug resistance mechanisms.
- For more information about the Company, please visit www.moleculin.com and connect on Twitter , LinkedIn and Facebook .
Retrieved on:
Wednesday, September 8, 2021
HOUSTON, Sept. 8, 2021 /PRNewswire/ --Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.
Key Points:
- HOUSTON, Sept. 8, 2021 /PRNewswire/ --Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.
- In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
- For more information about the conference, please visit the conference website .
- For more information about the Company, please visit www.moleculin.com and connect on Twitter , LinkedIn and Facebook .
